Dr. Nicole Stanton, Research Manager at the Cancer Society, said that the couple’s study is based on the exciting results of the Pitman group of the Wellington Victoria University, which recognized five early ovarian cancer potential biomarker.
“They hope to recognize the first ovarian cancer biomarkers screening panel, which can be used diagnostically to early detection, to enable rapid treatment and to increase the level of survival of five years.”
According to Stanton, ovarian cancer was the highest mortality rate of all Aotearo all gynecological cancers, but the early diagnosis dramatically improved the level of survival.
“At the moment, it’s really hard to detect. There is not a very good test to screen it, so for most people who have diagnosed ovarian cancer are diagnosed quite late. “
The work of Sczleck and Larnkham involves searching and assembling biomarkers tests.
“So they can screen ovarian cancer so that it is found earlier, and (what) you can detect it, like most cancers, the better you can do and the more it is in coping.”
Post -study scholarships were also awarded to Dr. Citra Praditi in Christchurch and Dr. Annuka Seddon from the University of Otago.
The Pradit study explores the role of vitamin C (ascorbate) in cancer, especially to understand the role that it could have in addition to supplementary melanoma therapy.
Seddon explores incorrect mitochondria to find new and better ways to handle acute myeloid ruokia.
Stanton said that a huge number of high quality applications were submitted this year.
“I’m particularly excited to see more funding for ovarian cancer research, which has been historically studied.”
– rnz
Register Daily hA free newsletter whose journalists curate and deliver directly to your mailbox every weekday.